A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.
Level II
Where this comes from
- Record sourced from PubMed, PMID 19210163.
- Also identified by DOI 10.1086/596558 and PMC identifier 2804070.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. Either 1 or 2 10(7)-TCID(50) doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 were administered intranasally to 50 adults in isolation; 41 participants were H9N2 seronegative, 24 of whom received 2 doses. The vaccine was well tolerated; vaccine shedding was minimal. After 2 doses, 92% of H9-seronegative participants had > or = 4-fold increases in hemagglutination-inhibition antibody, and 79% had > or = 4-fold increases in neutralizing antibody; 100% had responses detected by at least 1 assay. Although replication of the H9N2 LAIV was restricted, 2 doses were immunogenic in H9N2-seronegative adults. Trial registration. ClinicalTrials.gov identifier: NCT00110279 .
Medical subject headings
- Influenza A Virus, H9N2 Subtype
- Influenza Vaccines
- Influenza, Human